Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2022, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline landscape.
Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 11, 11, 12, 1, 17, 10 and 1 respectively.
Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ankylosing Spondylitis (Bekhterev's Disease) - Overview
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development
Ankylosing Spondylitis (Bekhterev's Disease) - Drug Profiles
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products
Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones
Featured News & Press Releases
Aug 17, 2022: NICE Recommends RINVOQ (upadacitinib) as a treatment option for active ankylosing spondylitis (AS) in adults
Jul 27, 2022: Mabpharm announces approval of clinical trial application of CMAB015 by the National Medical Products Administration of China
Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
Jul 20, 2022: Health Canada approves AbbVie's RINVOQ® (upadacitinib) for the treatment of adults with active ankylosing spondylitis
Jun 01, 2022: AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
May 02, 2022: FDA grants approval for AbbVie's Rinvoq to treat ankylosing spondylitis
Apr 11, 2022: Celltrion Healthcare announces the availability of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar in Canada
Jan 20, 2022: Lynk doses first patient in Phase II ankylosing spondylitis drug trial
Dec 28, 2021: Akeso's IL-17A monoclonal antibody (Gumokimab) completion of patient enrollment in phase II clinical trial for the treatment of ankylosing spondylitis
Dec 08, 2021: Xinkanghe XKH004 ankylosing spondylitis phase II clinical trial investigator meeting was successfully held
Oct 07, 2021: AbbVie's RINVOQ (upadacitinib) met primary and all ranked secondary endpoints in phase 3 study in ankylosing spondylitis
Jun 25, 2021: AbbVie provides update regarding RINVOQ (upadacitinib) in psoriatic arthritis and ankylosing spondylitis in the U.S.
Feb 16, 2021: Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz (adalimumab)
Jan 25, 2021: European Commission approves AbbVie's RINVOQ (Upadacitinib) for the treatment of Psoriatic Arthritis and Ankylosing Spondylitis
Dec 22, 2020: China IND application of recombinant anti-human IL-17A/F humanized monoclonal antibody injection for AS indication is accepted by CDE
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by 3SBio Inc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AbbVie Inc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Akeso Inc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AstraZeneca Plc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Avesthagen Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Beijing Eastern Biotech Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bio-Thera Solutions Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocad, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biogen Inc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bioviz Technologies Pvt Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by BioXpress Therapeutics SA, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Boehringer Ingelheim International GmbH, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bristol-Myers Squibb Co, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celltrion Inc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Clover Biopharmaceuticals Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by DNX Biopharmaceuticals Inc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Dyadic International Inc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Eli Lilly and Co, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Enzene Biosciences Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Foshan Rexie Biotechnology Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by FunPep Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Hualan Biological Engineering Inc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Iltoo Pharma, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Immunwork Inc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Izana Bioscience Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by JiangSu Qyuns Therapeutics Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Johnson & Johnson, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Luye Pharma Group Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Lynk Pharmaceutical Hangzhou Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mabpharm Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by MoonLake Immunotherapeutics, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mycenax Biotech Inc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by NeuClone Pty Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Nimbus Therapeutics LLC, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by North China Pharmaceutical Group New Drug Research and Development Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Outlook Therapeutics Inc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pharmapraxis, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by PKU V-Ming (Hefei) Biologics Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz International GmbH, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shandong Danhong Pharmaceutical Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Novamab Biopharmaceuticals Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Siam Bioscience Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by SinoCelltech Group Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by siRNAgen Therapeutics Corp, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by UCB SA, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Valin Technologies Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by XinThera Inc, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Zhejiang Yatai Pharmaceutical Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, 2022
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, 2022 (Contd..1)
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, 2022 (Contd..2)
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
